Form 4/A for OLMA Olema Pharmaceuticals, Inc.
Accepted 2023-09-05 00:00:00 ET · period of report 2023-08-16 · accession 0001415889-23-012898 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2023-09-05 | 2023-08-16 | OLMA | Harmon Cyrus | Dir | S - Sale | $10.14 | -15.0K | 1.02M | -1% | -$152.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-16 | S | D | 15,000 | $10.14 | 1,023,714 | D | — | — | (F2) On August 17, 2023, the reporting person filed a Form 4 that inadvertently excluded the weighted average sale price for the transaction. This amendment is being filed solely to report that the weighted average sale price for the transaction reported was $10.14, and the range of prices were between $9.765 and $10.65. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |